| Execution period | 60 months |
|---|
NSE filing, NSE: SMT. Summary written from the filing by ALFA Finder's alert engine.
Sahajanand Medical Technologies Ltd: key numbers
- Share price
- ₹487.75
- Market cap
- ₹4,958 Cr
- Revenue (annual)
- ₹1,210 Cr
- Net profit (annual)
- ₹65.28 Cr
- Promoter holding
- 36.20%
- FII holding
- 35.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sahajanand Medical Technologies Ltd
All →Sahajanand Medical Technologies Board Meeting Outcome
Sahajanand Medical Technologies' board appointed M/s Amit Jaste & Associates as Secretarial Auditor for FY 2026-27 to FY 2030-31. The appointment is subject to shareholder approval.
- Execution
- FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval
Sahajanand Medical Technologies Earnings Call Transcript: Key Takeaways
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
Sahajanand Medical Technologies Acquisition Worth ₹7.33 Cr
Sahajanand Medical's Irish subsidiary approved up to USD 7,80,000 investment in SNP Medical Corp. This lifts its stake to 17.19%, a related-party deal at arm's length.
- Value
- ₹7.33 Cr
- Execution
- Tentatively completed by 31 March 2027
Sahajanand Medical Technologies Investor Presentation: Key Takeaways
Q2 FY27 record: revenue ₹3,734mn (+24.7%), EBITDA ₹656mn (17.6% margin), PAT ₹265mn (+26.6%). H1 revenue ₹7,251mn (+24.9%). Growth led by Other and Shockwave-type SH products.
Sahajanand Medical Technologies Q2 FY27 Results: Net Profit ₹26.5 Cr, Up 26.8% YoY
Sahajanand Medical Technologies Ltd reported revenue from operations of ₹373.4 Cr (+24.7% YoY) and net profit of ₹26.5 Cr (+26.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹26.5 Cr · +26.8% YoY
Sahajanand Medical Technologies Legal & Regulatory
Sahajanand Medical Technologies received a GST DRC-01D recovery notice from Jharkhand tax authorities. The demand totals Rs. 34.29 lakh, which the company is contesting before appellate authorities.
- Value
- ₹0.34 Cr
Other other announcement announcements
All →Fundviser Capital (India) Other Announcement
Fundviser Capital's quarterly Regulation 32 statement confirms no deviation in use of preferential warrant proceeds. Funds utilised total ₹38.10 Crore against ₹79.44 Crore raised.
Austere Systems Other Announcement
Austere Systems appointed EquiBridgeX Advisors as its Investor Relations and Public Relations agency effective November 5, 2026. The filing states no fees or financial terms.
Kiri Industries Other Announcement
Kiri Industries filed the Crisil monitoring agency report for the quarter ended September 30, 2026. The report covers utilisation of preferential warrant issue proceeds with no deviations.
Dr. Agarwals Health Care Other Announcement
Dr. Agarwal's Health Care submitted ICRA's monitoring agency report for the quarter ended September 30, 2026. ICRA reports no material deviation in IPO proceeds utilisation.
Span Divergent Other Announcement
Span Divergent approved leasing Ahmedabad property to material subsidiary Dryfruit Factory LLP. Rent is capped at ₹3 lakh monthly under an arm's-length related-party transaction.
Cello World Other Announcement
Cello World's QIP monitoring report shows no fund deviation for the quarter ended September 2026. Object 1 is delayed, with Rs.1.51 crore unutilised.